Preventing side effects of CAR-T therapy for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have large B-cell lymphoma that did not respond to first treatment or came back within 12 months, or you have tried at least two prior treatments.
- You have at least one measurable tumor (visible on scans).
- You are generally well enough to carry out daily activities (ECOG score 0-2).
- Your blood counts and organ functions (kidney, liver, heart, lungs) are within acceptable ranges.
- You do not have active infections, certain past transplants, or serious heart or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.